Kairos Pharma Recognized for Innovative Approach to Cancer Drug Resistance at 2026 Pthinnacle Awards

Kairos Pharma Ltd. (NYSE American: KAPA) has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognized for its innovative approach to addressing cancer drug resistance. The clinical-stage biopharmaceutical company’s strategy centers on developing resistance-modulating treatments designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies.

The company’s lead candidate, ENV-105 (carotuximab), is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting this pathway, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This approach represents a significant shift in cancer treatment strategy, moving beyond simply developing new drugs to making existing treatments more durable and effective.

Currently, ENV-105 is advancing through clinical trials, including a Phase 2 study for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. These trials address significant unmet medical needs in oncology, where drug resistance remains a major barrier to long-term treatment success. The company’s focus on combination approaches aims to improve durability of response across multiple cancer indications, potentially extending the effectiveness of current standard-of-care treatments.

The recognition at the Pinnacle Awards underscores the growing importance of addressing cancer drug resistance in therapeutic development. As tumors develop resistance mechanisms, patients often face limited options after initial treatments fail. Kairos Pharma’s approach of modulating resistance pathways rather than simply introducing new cytotoxic agents represents an emerging paradigm in oncology research. The company’s work is particularly relevant given that drug resistance contributes significantly to cancer mortality and treatment failure across numerous cancer types.

Investors and stakeholders can find additional information about the company’s progress through its newsroom at https://ibn.fm/KAPA. It is important to note that ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The clinical trials are ongoing, and results will determine the future development path for this resistance-modulating approach to cancer treatment.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Kairos Pharma Recognized for Innovative Approach to Cancer Drug Resistance at 2026 Pthinnacle Awards.

The post Kairos Pharma Recognized for Innovative Approach to Cancer Drug Resistance at 2026 Pthinnacle Awards appeared first on citybuzz.